TY - JOUR
T1 - Eculizumab monotherapy for NMOSD
T2 - Data from PREVENT and its open-label extension
AU - the PREVENT Study Group
AU - Pittock, Sean J.
AU - Fujihara, Kazuo
AU - Palace, Jacqueline
AU - Berthele, Achim
AU - Kim, Ho Jin
AU - Oreja-Guevara, Celia
AU - Nakashima, Ichiro
AU - Levy, Michael
AU - Shang, Shulian
AU - Yountz, Marcus
AU - Miller, Larisa
AU - Armstrong, Róisín
AU - Wingerchuk, Dean M.
N1 - Publisher Copyright:
© The Author(s), 2021.
PY - 2022/3
Y1 - 2022/3
N2 - During PREVENT (a phase 3, randomized, double-blind, placebo-controlled, time-to-event study) and its open-label extension (interim analysis), 33 adults with aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder (AQP4-IgG + NMOSD) received eculizumab monotherapy for a median of 2.8 years (range, 14 weeks–5.2 years). At 192 weeks (~4 years), 96% of these patients were free from adjudicated relapses (Kaplan–Meier analysis; 95% confidence interval, 75.7–99.4). During PREVENT, 95% (20/21) of patients receiving eculizumab monotherapy had no disability worsening. Eculizumab monotherapy provides effective long-term relapse prevention, relieving the chronic immunosuppression burden in patients with AQP4-IgG + NMOSD. ClinicalTrials.gov; PREVENT: NCT01892345; open-label extension: NCT02003144.
AB - During PREVENT (a phase 3, randomized, double-blind, placebo-controlled, time-to-event study) and its open-label extension (interim analysis), 33 adults with aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder (AQP4-IgG + NMOSD) received eculizumab monotherapy for a median of 2.8 years (range, 14 weeks–5.2 years). At 192 weeks (~4 years), 96% of these patients were free from adjudicated relapses (Kaplan–Meier analysis; 95% confidence interval, 75.7–99.4). During PREVENT, 95% (20/21) of patients receiving eculizumab monotherapy had no disability worsening. Eculizumab monotherapy provides effective long-term relapse prevention, relieving the chronic immunosuppression burden in patients with AQP4-IgG + NMOSD. ClinicalTrials.gov; PREVENT: NCT01892345; open-label extension: NCT02003144.
KW - Clinical trial
KW - neuromyelitis optica (NMO)
UR - http://www.scopus.com/inward/record.url?scp=85114738337&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85114738337&partnerID=8YFLogxK
U2 - 10.1177/13524585211038291
DO - 10.1177/13524585211038291
M3 - Article
C2 - 34498507
AN - SCOPUS:85114738337
SN - 1352-4585
VL - 28
SP - 480
EP - 486
JO - Multiple Sclerosis Journal
JF - Multiple Sclerosis Journal
IS - 3
ER -